Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 13/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15426836 | 0.90 | L3MBTL1 (0.53) | CYP2C19HTR6HTTALDH1A1HPGD | |
| SCHEMBL3653359 | 0.88 | CYP2C19 (0.51) | CYP2C19HTR6HTTMEN1KMT2A | |
| SCHEMBL3255296 | 0.85 | CYP2C19 (0.48) | CYP2C19HTR6HTTMEN1KMT2A | |
| SCHEMBL1015374 | 0.80 | L3MBTL1 (0.52) | CYP2C19HTR6HTTALDH1A1LMNA | |
| SCHEMBL783771 | 0.79 | CYP2C19 (0.51) | CYP2C19HTR6HTTMEN1KMT2A | |
| SCHEMBL4724390 | 0.79 | L3MBTL1 (0.51) | HTR6HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL15728092 | 0.78 | L3MBTL1 (0.46) | CYP2C19HTR6HTTMEN1KMT2A | |
| SCHEMBL31410906 | 0.78 | CYP2C19 (0.50) | CYP2C19HTR6HTTMEN1KMT2A | |
| SCHEMBL31246107 | 0.78 | L3MBTL1 (0.50) | HTR6HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL4793803 | 0.78 | L3MBTL1 (0.50) | CYP2C19HTR6HTTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023125737-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | SILEXON AI TECHNOLOGY CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| US-20230148450-A9 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230148450-A9 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20220135584-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | REVOLUTION MEDICINES INC (US) | 2022-05-05 | — | — | US | disclosed |
| CN-113767100-A | Bicyclic heteroaryl compounds and uses thereof | 锐新医药公司 | 2021-12-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135584-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | CYP2C19 3440/4885HTR6 2484/4885HTT 3916/4885 |
| US-20230148450-A9 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | CYP2C19 3440/4885HTR6 2484/4885HTT 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.